Please assess the completion status of the following clinical trial:

Trial Title: Preventing Alcohol Withdrawal With Oral Baclofen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (\>21) admitted to inpatients units of 1 of 3 Essentia Health hospitals~* Patient placed on AWS watch protocol by admitting physicians.~Exclusion Criteria:~* Unable to provide informed consent~* Unable to take swallow oral medications (tube-fed patients are to be excluded)~* Admitted for AWS or with Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar) score \>8 at baseline~* No alcohol intake for ≥ 48 hours or AUDIT score \<12 at baseline~* Baclofen use at baseline~* Baclofen sensitivity~* Hospital discharge anticipated in within 48 hours~* Pregnant or breast feeding (urine pregnancy test required of women of child-bearing potential)~* Other active drug dependence (except tobacco)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo every eight hours as inpatients for 72 hours or until discharge if less than 72 hours.
- Baclofen (Type: ACTIVE_COMPARATOR): Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).